Search research articles
Contact Us
Filters
Showing results (201-210 of 247) with videos related to
Page
of 25
Sort By:
Molecular Cancer Therapeutics
|
December 13, 2002
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity
Judith R Kroep, Willem J P Loves, Clasina L van der Wilt, et al.
Circulation Research
|
December 30, 2020
Ca<sup>2+</sup>-CaM Dependent Inactivation of RyR2 Underlies Ca<sup>2+</sup> Alternans in Intact Heart
Jinhong Wei, Jinjing Yao, Darrell Belke, et al.
Frontiers in Neurology
|
November 8, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
Enrique Alvarez, Lawrence Steinman, Edward J Fox, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
August 15, 2017
Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals
Nananda F Col, Andrew J Solomon, Vicky Springmann, et al.
International Journal of MS Care
|
December 21, 2018
Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis
Nananda F Col, Andrew J Solomon, Vicky Springmann, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging
|
May 12, 2018
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS
Robert Zivadinov, Jennie Medin, Nasreen Khan, et al.
Scientific Reports
|
May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis
Delphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
Frontiers in Immunology
|
June 15, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Derrick Robertson, Enrique Alvarez, Lawrence Steinman, et al.
Journal of Neurology
|
September 13, 2012
Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease
Leo H Wang, Robert C Bucelli, Erica Patrick, et al.
JAMA Neurology
|
February 16, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study
Bruce A C Cree, Edward Fox, Hans-Peter Hartung, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 247) with videos related to
Sort By:
Page
of 25
Molecular Cancer Therapeutics
|
December 13, 2002
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity
Judith R Kroep, Willem J P Loves, Clasina L van der Wilt, et al.
Circulation Research
|
December 30, 2020
Ca<sup>2+</sup>-CaM Dependent Inactivation of RyR2 Underlies Ca<sup>2+</sup> Alternans in Intact Heart
Jinhong Wei, Jinjing Yao, Darrell Belke, et al.
Frontiers in Neurology
|
November 8, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
Enrique Alvarez, Lawrence Steinman, Edward J Fox, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
August 15, 2017
Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals
Nananda F Col, Andrew J Solomon, Vicky Springmann, et al.
International Journal of MS Care
|
December 21, 2018
Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis
Nananda F Col, Andrew J Solomon, Vicky Springmann, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging
|
May 12, 2018
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS
Robert Zivadinov, Jennie Medin, Nasreen Khan, et al.
Scientific Reports
|
May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis
Delphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
Frontiers in Immunology
|
June 15, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Derrick Robertson, Enrique Alvarez, Lawrence Steinman, et al.
Journal of Neurology
|
September 13, 2012
Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease
Leo H Wang, Robert C Bucelli, Erica Patrick, et al.
JAMA Neurology
|
February 16, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study
Bruce A C Cree, Edward Fox, Hans-Peter Hartung, et al.
Page
of 25